{"id":"W2326276419","doi":"10.1158/1557-3125.advbc-a050","title":"Abstract A050: ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Neratinib; Limiting; Pharmacokinetics; Pharmacology; Adverse effect; Clinical trial; Internal medicine; Oncology; Maximum tolerated dose; Trastuzumab; Breast cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001013783,0.001047767,0.000927951,0.0004152368,0.0002967298,0.0008515587,0.0008879636,0.0008406105,0.006102827],"category_scores_gemma":[0.00047641,0.0003533449,0.000698404,0.0002873909,0.0003734094,0.0004309714,0.0002766394,0.00217268,0.001456335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007809633,"about_ca_system_score_gemma":0.001723286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001803331,"about_ca_topic_score_gemma":0.004254549,"domain_scores_codex":[0.9997734,0.00005518109,0.00001203504,0.00003402232,0.00006006433,0.00006530619],"domain_scores_gemma":[0.9997241,0.00002858526,0.00004136599,0.00001621334,0.0000509396,0.0001389042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1431089,0.0488747,0.009427167,0.003925012,0.00239432,0.001359475,0.0006057417,0.01122891,0.2948097,0.002057672,0.1156653,0.3665431],"study_design_scores_gemma":[0.1600336,0.5857809,0.03291821,0.0003993891,0.002024953,0.003223167,0.0001922783,0.009300162,0.1024442,0.001872887,0.1016543,0.0001560795],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9241363,0.01844287,0.007138804,0.002339666,0.0005419673,0.008390024,0.01993836,0.001159263,0.01791268],"genre_scores_gemma":[0.9198923,0.01172163,0.008934063,0.003438294,0.0002442107,0.004370373,0.02448525,0.000229817,0.02668408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006102827,"threshold_uncertainty_score":0.02041602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1471978799053764,"score_gpt":0.5059109550626726,"score_spread":0.3587130751572961,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}